[ back to News ]

CoNCERT Pharmaceuticals to Present at the
Cowen and Company 28th Annual Healthcare Conference

March 11, 2008

LEXINGTON, MASS. — Concert Pharmaceuticals, Inc.™, the first company dedicated to creating safer, more effective medicines using precision deuterium chemistry, announced today that it will be presenting at the Cowen and Company 28th Annual Healthcare Conference, being held at the Boston Marriott Copley Place in Boston, Massachusetts. Roger Tung, Ph.D., President and Chief Executive Officer of CoNCERT, will present an overview of the Company on Tuesday, March 18, 2008 at 9:00 a.m. (ET).

About CoNCERT

CoNCERT Pharmaceuticals is the first company dedicated to creating new medicines through a novel scientific approach utilizing the naturally-occurring element deuterium. CoNCERT applies its innovative precision chemistry platform to modify specific properties of validated drug molecules, yielding a rich pipeline of new chemical entities (NCEs). CoNCERT leverages decades of pharmaceutical experience to create drug candidates with potential for best-in-class efficacy and safety, while greatly reducing R&D risk, time and expense. The Company has over 100 patent applications for new drug candidates addressing a broad range of therapeutic areas, including hot flashes, fibrotic diseases, pain and infectious disease. CoNCERT expects to initiate its first clinical study in 2008. More information on CoNCERT can be found on the Company’s website at http://www.concertpharma.com.

[ back to top ]